PRKDC and neoplasm: In conclusion, the therapeutic potential of DNA-PKcs inhibition is shaped by complex molecular determinants, including tumor-specific PRKDC mutation profiles, compensatory signaling within the PIKK family, and synergistic interactions with DDR deficiencies.